Ludwig-Maximilians-Universitat Munchen

München, Bavaria 81377

0 studies enrolling now · 3 studies all time

What they study most

ALK-positive Advanced NSCLC, Pulmonary Arterial Hypertension

Studies at this site

• A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib — Completed
• An Open-Label, Long-Term Study of Oral Treprostinil in Subjects With Pulmonary Arterial Hypertension — Completed
• Phase III Clinical Worsening Study of UT-15C in Subjects With PAH Receiving Background Oral Monotherapy — Completed